Publicaciones en colaboración con investigadores/as de University of Florence (5)

2025

  1. Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS

    Blood Advances, Vol. 9, Núm. 16, pp. 4090-4099

2024

  1. Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study

    British Journal of Haematology, Vol. 205, Núm. 5, pp. 1734-1745

  2. Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study

    Leukemia, Vol. 38, Núm. 10, pp. 2259-2265

2018

  1. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

    Leukemia, Vol. 32, Núm. 12, pp. 2546-2557

2017

  1. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents

    Journal of Clinical Oncology, Vol. 35, Núm. 14, pp. 1591-1597